Activating mutations in FGFR3 tyrosine kinase cause several forms of human skeletal dysplasia. Although the mechanisms of FGFR3 action in cartilage are not completely understood, it is believed that the STAT1 transcription factor plays a central role in pathogenic FGFR3 signaling. Here, we analyzed STAT1 activation by the N540K, G380R, R248C, Y373C, K650M and K650E-FGFR3 mutants associated with skeletal dysplasias. In a cell-free kinase assay, only K650M and K650E-FGFR3 caused activatory STAT1(Y701) phosphorylation. Similarly, in RCS chondrocytes, HeLa, and 293T cellular environments, only K650M and K650E-FGFR3 caused strong STAT1 activation. Other FGFR3 mutants caused weak (HeLa) or no activation (293T and RCS). This contrasted with ERK MAP kinase activation, which was strongly induced by all six mutants and correlated with the inhibition of proliferation in RCS chondrocytes. Thus the ability to activate STAT1 appears restricted to the K650M and K650E-FGFR3 mutants, which however account for only a small minority of the FGFR3-related skeletal dysplasia cases. Other pathways such as ERK should therefore be considered as central to pathological FGFR3 signaling in cartilage.

Department of Animal Physiology and Immunology Institute of Experimental Biology Masaryk University Brno Czech Republic

Zobrazit více v PubMed

Passos-Bueno MR, Wilcox WR, Jabs EW, Sertié AL, Alonso LG, et al. Clinical spectrum of fibroblast growth factor receptor mutations. Hum Mutat. 1999;14:115–125. PubMed

Horton WA, Hall JG, Hecht JT. Achondroplasia. Lancet. 2007;370:162–172. PubMed

Ornitz DM. FGF signaling in the developing endochondral skeleton. Cytokine Growth Factor Rev. 2005;16:205–213. PubMed PMC

L'Hôte CGM, Knowles MA. Cell responses to FGFR3 signaling: growth, differentiation and apoptosis. Exp Cell Res. 2005;304:417–431. PubMed

Su W-CS, Kitagawa M, Xue N, Xie B, Garofalo S, et al. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. Nature. 1997;386:288–291. PubMed

Hart KC, Robertson SC, Donoghue DJ. Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, stat activation, and phosphatidylinositol 3-kinase activation. Mol Biol Cell. 2001;12:931–942. PubMed PMC

Ronchetti D, Greco A, Compasso S, Colombo G, Dell'Era P. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene. 2001;20:3553–3562. PubMed

Lievens PM-J, Mutinelli C, Baynes D, Liboi E. The kinase activity of fibroblast growth factor receptor 3 with activation loop mutations affects receptor trafficking and signaling. J Biol Chem. 2004;279:43254–43260. PubMed

Nowroozi N, Raffioni S, Wang T, Apostol BL, Bradshaw RA. Sustained Erk1/2 but not STAT1 or 3 activation is required for thanatophoric dysplasia phenotypes in PC12 cells. Hum Mol Genet. 2005;14:1529–1538. PubMed

Harada D, Yamanaka Y, Ueda K, Nishimura R, Morishima T. Sustained phosphorylation of mutated FGFR3 is crucial feature of genetics dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCγ-activated STAT1. Bone. 2007;41:273–281. PubMed

Krejci P, Kashiwada TA, Goodridge HS, Salazar L, Schibler M, et al. STAT1 and STAT3 do not participate in fibroblast growth factor-mediated growth arrest in chondrocytes. J Cell Sci. 2008;121:272–281. PubMed

Legeai-Mallet L, Benoist-Lasselin C, Munnich A, Bonaventure J. Overexpression of FGFR3, Stat1, Stat5 and p21Cip1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias. Bone. 2004;34:26–36. PubMed

Li C, Chen L, Iwata T, Kitagawa M, Fu X, et al. A lys644glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors. Hum Mol Genet. 1999;8:35–41. PubMed

Sahni M, Ambrosetti D, Mansukhani A, Gertner R, Levy D, et al. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev. 1999;13:1361–1366. PubMed PMC

Sahni M, Raz R, Coffin JD, Levy D, Basilico C. Stat1 mediates the increased apoptosis and reduced chondrocyte proliferation in mice overexpressing FGF2. Development. 2001;128:2119–2129. PubMed

Murakami S, Balmes G, McKinney S, Zhang Z, Givol D, et al. Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype. Genes Dev. 2004;18:290–305. PubMed PMC

Raucci A, Laplantine E, Mansukhani A, Basilico C. Activation of the Erk1/2 and p38 mitogen-activated protein kinase pathways mediates fibroblast growth factor-induced growth arrest of chondrocytes. J Biol Chem. 2004;279:1747–1756. PubMed

Krejci P, Bryja V, Pachernik J, Hampl A, Pogue R, et al. FGF2 inhibits proliferation and alters the cartilage-like phenotype of RCS cells. Exp Cell Res. 2004;297:152–164. PubMed

Matsushita T, Wilcox WR, Chan YY, Kawanami A, Bukulmez H, et al. FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway. Hum Mol Genet. In press 2008 PubMed PMC

Colvin JS, Bohne BA, Harding GW, McEwen DG, Ornitz DM. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat Genet. 1996;12:390–397. PubMed

Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, et al. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene. 2000;19:3309–3320. PubMed

Lievens PM-J, Liboi E. The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum. J Biol Chem. 2003;278:17344–17349. PubMed

Krejci P, Masri B, Salazar L, Farrington-Rock C, Prats H, et al. Bisindolylmaleimide I suppresses fibroblast growth factor-mediated activation of Erk MAP kinase in chondrocytes by preventing Shp2 association with the Frs2 and Gab1 adaptor proteins. J Biol Chem. 2007;282:2929–2936. PubMed

d'Avis PY, Robertson SC, Meyer AN, Bardwell WM, Webster MK, et al. Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I. Cell Growth Diff. 1998;9:71–78. PubMed

Webster MK, d'Avis PY, Robertson SC, Donoghue DJ. Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II. Mol Cell Biol. 1996;16:4081–4087. PubMed PMC

Aikawa T, Segre GV, Lee K. Fibroblast growth factor inhibits chondrocytic growth through induction of p21 and subsequent inactivation of cyclin E-Cdk2. J Biol Chem. 2001;276:29347–29352. PubMed

Rozenblatt-Rosen O, Mosonego-Ornan E, Sadot E, Madar-Shapiro L, Sheinin Y, et al. Induction of chondrocyte growth arrest by FGF: transcriptional and cytoskeletal alterations. J Cell Sci. 2002;115:553–562. PubMed

Krejci P, Masri B, Fontaine V, Mekikian PB, Weis M, et al. Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis. J Cell Sci. 2005;118:5089–5100. PubMed

Dailey L, Laplantine E, Priore R, Basilico C. A network of transcriptional and signaling events is activated by FGF to induce chondrocyte growth arrest and differentiation. J Cell Biol. 2003;161:1053–1066. PubMed PMC

Yasoda A, Komatsu Y, Chusho H, Miyazawa T, Ozasa A, et al. Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. Nat Med. 2004;10:80–86. PubMed

Legeai-Mallet L, Benoist-Lasselin C, Delezoide A, Munnich A, Bonaventure J. Fibroblast growth factor receptor 3 mutations promote apoptosis but do not alter chondrocyte proliferation in thanatophoric dysplasia. J Biol Chem. 1998;273:13007–13014. PubMed

Plowright EE, Li Z, Bergsagel PL, Chesi M, Barber DL, et al. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood. 2000;95:992–998. PubMed

Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. Science. 2002;296:1653–1655. PubMed

Fibroblast growth factor receptor 3 interacts with and activates TGFβ-activated kinase 1 tyrosine phosphorylation and NFκB signaling in multiple myeloma and bladder cancer

Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias

FGFR3 signaling induces a reversible senescence phenotype in chondrocytes similar to oncogene-induced premature senescence